Callie Wells, APRN
Payments from drug & device makers
Across 399 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$910
- Mannkind Corporation$485
- Corcept Therapeutics$471
- Insulet Corporation$447
- Lilly USA, LLC$438
- plus $3K from 24 others
What the payments were for
- Travel & lodging$1,08614%
- Food & beverage$6,48185%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 41 | $1,897 |
| Novo Nordisk | 59 | $910 |
| Mannkind Corporation | 34 | $485 |
| Corcept Therapeutics | 29 | $471 |
| Insulet Corporation | 31 | $447 |
| Lilly USA, LLC | 30 | $438 |
| Amgen(2 entities) | 31 | $425 |
| Boehringer Ingelheim | 25 | $423 |
| Bayer | 18 | $318 |
| Tandem Diabetes Care, Inc. | 18 | $318 |
| BETA Bionics, Inc. | 12 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $175 |
| AbbVie | 7 | $120 |
| AstraZeneca | 7 | $105 |
| Dexcom, Inc. | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| Novartis | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Astellas Pharma US Inc | 4 | $72 |
| Ascendis Pharma Endocrinology Inc | 4 | $68 |
| Radius Health, Inc. | 4 | $66 |
| Ascensia Diabetes Care US Inc. | 3 | $65 |
| Kyowa Kirin, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Abbott | 2 | $37 |
| Medline Industries LP | 1 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Genentech USA, Inc. | 3 | $21 |
| Sequel Med Tech, LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,168
How this compares
$7,592 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $259,958 |
| MounjaroTirzepatide | 100 | $121,894 |
| JardianceEmpagliflozin | 112 | $110,639 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 78 | $81,084 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $52,420 |
| KerendiaFinerenone | 54 | $47,418 |
| TrulicityDulaglutide | 23 | $36,321 |
| FarxigaDapagliflozin Propanediol | 30 | $34,822 |
| Humulin R U-500Insulin Regular, Human | 21 | $33,847 |
| Repatha SureclickEvolocumab | 37 | $25,727 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $25,157 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $23,411 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $18,107 |
| Novolog FlexpenInsulin Aspart | 78 | $17,268 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $16,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $910 | $285,128225 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $438 | $160,232139 claims |
| Boehringer IngelheimJardiance | $423 | $110,639112 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $81,08478 claims |
| BayerKerendia | $318 | $47,41854 claims |
| AstraZenecaFarxiga | $105 | $34,82230 claims |
| AbbVieSynthroid | $120 | $1,53819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Cadiz
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.